Alterity Therapeutics Reports ATH434 Slowed MSA Decline by 52% in Phase 2 Trial
New analyses of ATH434 phase 2 data show the drug significantly slowed functional decline in multiple system atrophy versus placebo over one year.
Alterity Therapeutics presented new analyses of its ATH434 phase 2 clinical trial data at the 2026 International Congress of Parkinson's Disease and Movement Disorders, highlighting promising results for patients with multiple system atrophy, a rare and rapidly progressive neurodegenerative disease.
The 50 mg dose of ATH434 slowed functional decline in multiple system atrophy by approximately 52% compared to placebo on the 11-item Unified Multiple System Atrophy Rating Scale, known as UMSARS, measured at Week 52. The analysis incorporated cerebrospinal fluid neurofilament light chain, or CSF NfL, as a statistical covariate, a biomarker increasingly used to track neurodegeneration severity.
Read more SignSplit Raises $400M Seed Round at $1B Valuation →
Multiple system atrophy is an orphan disease with no approved disease-modifying treatments, making any clinical signal of slowed progression a significant development for the field. The UMSARS is a widely accepted clinical tool for measuring functional impairment in MSA patients, and a 52% reduction in decline over a year represents a clinically meaningful benchmark if confirmed in later-stage trials.
The presentation at one of the world's leading movement disorders conferences provides the scientific community with an opportunity to scrutinize the methodology behind ATH434's efficacy data, including the role of CSF NfL as a prognostic biomarker and covariate in the statistical model. Analysts and clinicians will be watching how the company interprets these findings as it charts a path toward potential regulatory discussions.
Continue reading at GlobeNewswire - Industry News on Financial Services
